{
    "clinical_study": {
        "@rank": "111068", 
        "arm_group": {
            "arm_group_label": "Cohorts 1 - 4", 
            "arm_group_type": "Experimental", 
            "description": "Participants in cohort 1 will receive REGN2176-3 dosing regimen 1. Participants in cohort 2 will receive REGN2176-3 dosing regimen 2. Participants in cohort 3 will receive REGN2176-3 dosing regimen 3. Participants in cohort 4 will receive REGN2176-3 dosing regimen 4."
        }, 
        "brief_summary": {
            "textblock": "The primary objective of the study is to investigate the safety of intravitreal (IVT)\n      REGN2176-3 in patients with neovascular wet age-related macular degeneration (AMD)."
        }, 
        "brief_title": "Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Neovascular Wet Age-related Macular Degeneration (AMD)", 
        "condition_browse": {
            "mesh_term": "Macular Degeneration"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Key Criteria:\n\n        Men or women greater than or equal to 50 years of age who provide informed consent and\n        have active subfoveal choroidal neovascularization (CNV) secondary to wet AMD.\n\n        Exclusion Criteria:\n\n          1. Any prior treatment with an inhibitor of PDGF (platelet-derived growth factor) or\n             PDGFR (platelet-derived growth factor receptor)\n\n          2. Active neovascular AMD in the fellow eye requiring treatment\n\n          3. Scar, fibrosis, or atrophy in the study eye involving the center of the fovea\n\n          4. Presence of retinal pigment epithelial tears or rips involving the macula in the\n             study eye\n\n          5. Prior vitrectomy in the study eye\n\n          6. Any history of macular hole of stage 2 and above in the study eye\n\n          7. Any intraocular or periocular surgery within 3 months of day 1 in the study eye,\n             except lid surgery\n\n          8. History of corneal transplant in the study eye\n\n          9. Positive serum human chorionic gonadotropin (hCG)/ urine pregnancy test at the\n             screening or baseline visit\n\n        The information listed above is not intended to contain all considerations relevant to a\n        patient's potential participation in this clinical trial and not all inclusion/ exclusion\n        criteria are listed."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02061865", 
            "org_study_id": "R2176-3-AMD-1303"
        }, 
        "intervention": {
            "arm_group_label": "Cohorts 1 - 4", 
            "intervention_name": "REGN2176-3", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "February 11, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beverly Hills", 
                        "country": "United States", 
                        "state": "California"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Colorado Springs", 
                        "country": "United States", 
                        "state": "Colorado"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "overall_contact": {
            "email": "clinicaltrials@regeneron.com", 
            "last_name": "Clinical Trials Administrator"
        }, 
        "overall_official": {
            "affiliation": "Regeneron Pharmaceuticals", 
            "last_name": "Clinical Trial Management", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint in the study is the incidence of treatment emergent adverse events (TEAEs) from day 1 through week 24 in patients treated with IVT REGN2176-3.", 
            "measure": "Safety", 
            "safety_issue": "Yes", 
            "time_frame": "day 1 through week 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02061865"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Regeneron Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Regeneron Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}